## 505582613 07/22/2019 PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT5629412

SUBMISSION TYPE:		NEW ASSIGNMENT					
NATURE OF CONVEYANCE:			NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY				
CONVEYING PARTY	DATA						
		I	Name			Execution Date	
STRATATECH CORP	ORATION					07/19/2019	
RECEIVING PARTY	ΟΑΤΑ						
Name:	DEUTS	DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT					
Street Address:	60 WAL	60 WALL STREET					
City:	NEW Y	NEW YORK					
State/Country:	NEW Y	NEW YORK					
Postal Code:	10005	10005					
Property Type		10000	Number				
PROPERTY NUMBER	RS Total: 2						
		10000					
• •		16036619 16122598					
Application Number:		10122	2398				
<i>using a fax number,</i> Phone: Email: Correspondent Name Address Line 1: Address Line 4:	l be sent to if provided e:	<i>; if th</i> 21362 ipreco JUST 555 S	e-mail address first; if that is unat is unsuccessful, it will be s 207848 ordations@whitecase.com INE LU/WHITE & CASE LLP SOUTH FLOWER STREET, 2700 ANGELES, CALIFORNIA 90071	sent			
ATTORNEY DOCKET	NUMBER:		1111779-2659-S216				
NAME OF SUBMITTER:		JUSTINE LU					
SIGNATURE:			/Justine Lu/				
DATE SIGNED:			07/22/2019				
DATE SIGNED:							

PATENT REEL: 049823 FRAME: 0302

#### Notice of Grant of Security Interest in Intellectual Property

NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS, dated as of July 19, 2019 (this "*Agreement*"), made by Stratatech Corporation, a Delaware corporation (the "*Pledgor*"), in favor of DEUTSCHE BANK AG NEW YORK BRANCH, as Collateral Agent (as defined below).

Reference is made to the U.S. Collateral Agreement dated as of March 19, 2014 (as amended, restated, supplemented or otherwise modified from time to time, the "U.S. Collateral Agreement"), among Mallinckrodt International Finance S.A., a public limited liability company (société anonyme) incorporated under the laws of the Grand Duchy of Luxembourg, having its registered office at 124, boulevard de la Pétrusse, L-2330 Luxembourg, and registered with the Luxembourg Trade and Companies Register (R.C.S. Luxembourg) under number B 172.865 (the "Lux Borrower"), MALLINCKRODT CB LLC (the "Co-Borrower", and together with the Lux Borrower, the "Borrowers"), Mallinckrodt Holdings GmbH (as successor by merger to Mallinckrodt Finance GmbH) (the "Swiss Finco"), each other Subsidiary Loan Party listed on the signature pages hereof and each other Subsidiary Loan Party that becomes a party hereto after the date hereof and DEUTSCHE BANK AG NEW YORK BRANCH, as collateral agent (together with its successors and assigns in such capacity, the "Collateral Agent") for the Secured Parties (as defined therein). The parties hereto agree as follows:

SECTION 1. *Terms*. Capitalized terms used in this Agreement and not otherwise defined herein have the meanings specified in the U.S. Collateral Agreement. The rules of construction specified in Section 1.01(b) of the U.S. Collateral Agreement also apply to this Agreement.

SECTION 2. *Grant of Security Interest*. As security for the payment and performance, as applicable, in full of its Secured Obligations, the Pledgor pursuant to the U.S. Collateral Agreement did, and hereby does, assign and pledge to the Collateral Agent, its successors and permitted assigns, for the benefit of the Secured Parties, a continuing security interest in all of such Pledgor's right, title and interest in, to and under any and all of the following assets now owned or at any time hereafter acquired by such Pledgor or in which such Pledgor now has or at any time in the future may acquire any right, title or interest (collectively, but excluding any Excluded Property, the "<u>IP Collateral</u>"):

all Patents of the United States of America, including those listed on Schedule I;

SECTION 3. U.S. Collateral Agreement. The security interests granted to the Collateral Agent herein are granted in furtherance, and not in limitation of, the security interests granted to the Collateral Agent pursuant to the U.S. Collateral Agreement. The Pledgor hereby acknowledges and affirms that the rights and remedies of the Collateral Agent with respect to the IP Collateral are more fully set forth in the U.S. Collateral Agreement, the terms and provisions of which are hereby incorporated herein by reference as if fully set forth herein. In the event of any conflict between the terms of this Agreement and the U.S. Collateral Agreement, the terms of the U.S. Collateral Agreement shall govern.

PATENT REEL: 049823 FRAME: 0303 SECTION 4. *Counterparts*. This Agreement may be executed in two or more counterparts, each of which shall constitute an original but all of which when taken together shall constitute but one contract. Delivery of an executed counterpart to this Agreement by facsimile or other electronic transmission shall be as effective as delivery of a manually signed original.

SECTION 5. Governing Law. THIS AGREEMENT AND ANY CLAIMS, CONTROVERSY, DISPUTE OR CAUSES OF ACTION (WHETHER IN CONTRACT OR TORT OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATING TO THIS AGREEMENT SHALL BE CONSTRUED IN ACCORDANCE WITH AND GOVERNED BY THE LAWS OF THE STATE OF NEW YORK.

[Signature Pages Follow]

IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement as of the day and year first above written.

### STRATATECH CORPORATION

By:

Nam: John Einwalter Title Vice President & Treasurer

[Signature Page to Notice of Grant of Security Interest in Patents]

REEL: 049823 FRAME: 0305

DEUTSCHE BANK AG NEW YORK BRANCH, as Collateral Agent,

By: Name: Yumi Okabe Title: Vice President By Name: Alicia Schug Vice President/ Title:

[Signature Page to Notice of Grant of Security Interest in Patents]

PATENT REEL: 049823 FRAME: 0306

# Schedule I to Notice of Grant of Security Interest in Patents

## U.S. Patent Registrations

N/A

### U.S. Patent Applications

Patent	Application No.	Application Date	Owner
HUMAN SKIN EQUIVA-	16/036619	July 16, 2018	Stratatech Cor-
LENTS ENGINEERED TO			poration
EXPRESS EXOGENOUS			
ANTIMICROBIAL POLY-			
PEPTIDES			
CRYOPRESERVATION OF	16/122598	September 5,	Stratatech Cor-
VIABLE HUMAN SKIN		2018	poration
SUBSTITUTES			